Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: Responses to disease induction and therapy with the estrogen receptor-β selective agonist ERB-041

Endocrinology

Volumn 147, Issue 2, 2006, Pages 714-723

  Follettie, Maximillian T ^a   Pinard, Marc ^b   Keith Jr , James C ^a   Wang, Lili ^a   Chelsky, Daniel ^b   Hayward, Clive ^b   Kearney, Paul ^b   Thibault, Pierre ^b   Paramithiotis, Eustache ^b   Dorner, Andrew J ^a   Harris, Heather A ^a  

^a PFIZER INC   (United States)

^b Caprion Pharmaceuticals   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 FLUORO 4 HYDROXYPHENYL) 7 VINYL 5 BENZOXAZOLOL; ANTIINFLAMMATORY AGENT; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA AGONIST; FATTY ACID; ICOSANOID; IRON; PROTEOME; RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; FATTY ACID METABOLISM; GENE EXPRESSION; HUMAN; ICOSANOID METABOLISM; IRON METABOLISM; LIVER; LYMPH NODE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SPLEEN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD PROTEINS; ESTROGEN RECEPTOR BETA; GENE EXPRESSION PROFILING; LIVER; LYMPH NODES; MALE; ORGAN SPECIFICITY; OXAZOLES; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; RNA, MESSENGER; SPLEEN;

EID: 30944450977     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2005-0600     Document Type: Article

References (60)

1. Coleman KM, Smith CL 2001 Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci 6:D1379-D1391
2. Levin ER 2001 Genome and hormones: gender differences in physiology - invited review: cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol 91:1860-1867
3. Couse JF, Hewitt SC, Korach KS 2000 Receptor null mice reveal contrasting roles for estrogen receptor α and β in reproductive tissues. J Steroid Biochem Mol Biol 74:287-296
4. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS 2002 Characterization of the biological roles of the estrogen receptors, ERα and ERβ, in estrogen target tissues in vivo through the use of an ERα-selective ligand. Endocrinology 143:4172-4177
5. Hegele-Hartung C, Siebel P, Peters O, Kosemund D, Muller G, Hillisch A, Walter A, Kraetzschmar J, Fritzemeier KH 2004 Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc Natl Acad Sci USA 101:5129-5134
6. An JP, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC 2001 Estrogen receptor β-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 276:17808-17814
7. Shim GJ, Wang L, Andersson S, Nagy N, Kis LL, Zhang Q, Makela S, Warner M, Gustafsson JA 2003 Disruption of the estrogen receptor β gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. Proc Natl Acad Sci USA 100:6694-6699
8. Curran EM, Berghaus LJ, Vernetti NJ, Saporita AJ, Lubahn DB, Estes DM 2001 Natural killer cells express estrogen receptor-α and estrogen receptor-β and can respond to estrogen via a non-estrogen receptor-α-mediated pathway. Cell Immunol 214:12-20
9. Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith Jr JC 2003 Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 144:4241-4249
10. Jansson L, Holmdahl R 1998 Estrogen-mediated suppression in autoimmune diseases. Inflamm Res 47:290-301
11. Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, Straub RH 2004 Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 13:635-638
12. Polanczyk M, Zamora A, Subramanian S, Matejuk A, Hess DL, Blankenhorn EP, Teuscher C, Vandenbark AA, Offner H 2003 The protective effect of 17β-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-α. Am J Pathol 163:1599-1605
13. Matejuk A, Dwyer J, Zamora A, Vandenbark AA, Offner H 2002 Evaluation of the effects of 17β-estradiol (17∵-E2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray. Endocrinology 143:313-319
14. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B 2002 Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 109:1625-1633
15. Carlsten H, Tarkowski A, Holmdahl R, Nilsson LA 1990 Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice. Clin Exp Immunol 80:467-473
16. Jansson L, Holmdahl R 2001 Enhancement of collagen-induced arthritis in female mice by estrogen receptor blockage. Arthritis Rheum 44:2168-2175
17. Badger AM, Blake SM, Dodds RA, Griswold DE, Swift BA, Rieman DJ, Stroup GB, Hoffman SJ, Gowen M 1999 Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis. J Pharmacol Exp Ther 291:1380-1386
18. Brennan P, Bankhead C, Silman A, Symmons D 1997 Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum 26:817-823
19. Nicholas NS, Panayi GS 1988 Rheumatoid arthritis and pregnancy. Clin Exp Rheumatol 6:179-182
20. D'Elia HF, Larsen A, Mattsson LA, Waltbrand E, Kvist G, Mellstrom D, Saxne T, Ohlsson C, Nordborg E, Carlsten H 2003 Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 30:1456-1463
21. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802
22. Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD, Miller CP, Dinh T, Henderson RA, Keith Jr JC, Harris HA 2004 Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands. J Med Chem 47:5021-5040
23. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL 1996 Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14:1675-1680
24. Hill AA, Brown EL, Whitley MZ, Tucker-Kellogg G, Hunter CP, Slonim DK 2001 Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls. Genome Biol 2:RESEARCH0055.1-0055.13
25. Nilsson S, Kuiper G, Gustafsson JA 1998 ERβ: a novel estrogen receptor offers the potential for new drug development. Trends Endocrinol Metab 9:387-395
26. Walf AA, Rhodes ME, Frye CA 2004 Antidepressant effects of ERβ-selective estrogen receptor modulators in the forced swim test. Pharmacol Biochem Behav 78:523-529
27. Hillisch A, Peters O, Kosemund D, Muller G, Walter A, Schneider B, Reddersen G, Elger W, Fritzmeier KH 2004 Dissecting physiological roles of estrogen receptor α and β with potent selective ligands from structure-based design. Mol Endocrinol 18:1599-1609
28. Lin MK, Farewell V, Vadas P, Bookman AA, Keystone EC, Pruzanski W 1996 Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol 23:1162-1166
29. Thwin MM, Douni E, Aidinis V, Kollias G, Kodama K, Sato K, Satish RL, Mahendran R, Gopalakrishnakone P 2004 Effect of phospholipase A(2) inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res Ther 6:R282-R294
30. Griffiths RJ, Smith MA, Roach ML, Stock JL, Stam EJ, Milici AJ, Scampoli DN, Eskra JD, Byrum RS, Koller BH, McNeish JD 1997 Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J Exp Med 185:1123-1129
31. Sperling R, Benincaso A, Anderson R, Coblyn J, Austen K, Weinblatt M 1992 Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 35:376-384
32. Fitzsimons EJ, Sturrock RD 2002 The chronic anaemia of rheumatoid arthritis: iron banking or blocking? Lancet 360:1713-1714
33. Das Gupta A, Abbi A 2003 High serum transferrin receptor level in anemia of chronic disorders indicates coexistent iron deficiency. Am J Hematol 72:158-161
34. Yang J, Goetz D, Li JY, Wang WG, Mori K, Setlik D, Du TG, Erdjument-Bromage H, Tempst P, Strong R, Barasch J 2002 An iron delivery pathway mediated by a lipocalin. Mol Cell 10:1045-1056
35. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK 2002 The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10:1033-1043
36. Newton RA, Hogg N 1998 The human s100 protein mrp-14 is a novel activator of the β(2) integrin mac-1 on neutrophils. J Immunol 160:1427-1435
37. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, Harms E, Sorg C, Roth J 2000 Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 43:628-637
38. Foell D, Frosch M, Sorg C, Roth J 2004 Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 344:37-51
39. Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, Foell D, Sorg C, Sunderkotter C, Roth J 2003 Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 48:2622-2626
40. Drynda S, Ringel B, Kekow M, Kuhne C, Drynda A, Glocker MO, Thiesen HJ, Kekow J 2004 Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFα therapy. Pathol Res Pract 200:165-171
41. Wu SM, Patel DD, Pizzo SV 1998 Oxidized α(2)-macroglobulin (α(2)m) differentially regulates receptor binding by cytokines growth factors - implications for tissue injury and repair mechanisms in inflammation. J Immunol 161:4356-4365
42. Zapico I, Coto E, Rodriguez A, Alvarez C, Torre JC, Alvarez V 2000 A DNA polymorphism at the α2-macroglobulin gene is associated with the severity of rheumatoid arthritis. J Rheumatol 27:2308-2311
43. Couture R, Harrisson M, Vianna RM, Cloutier F 2001 Kinin receptors in pain and inflammation. Eur J Pharmacol 429:161-176
44. Espinola RG, Uknis A, Sainz IM, Isordia-Salas I, Pixley R, DeLa Cadena R, Long W, Agelan A, Gaughan J, Adam A, Colman RW 2004 A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis. Am J Pathol 165:969-976
45. Olmez U, Garred P, Mollnes T, Harboe M, Berntzen H, Munthe E 1991 C3 activation products, C3 containing immune complexes, the terminal complement complex and native C9 in patients with rheumatoid arthritis. Scand J Rheumatol 20:183-189
46. Liu X, Piela-Smith T 2000 Fibrin(ogen)-induced expression of ICAM-1 and chemokines in human synovial fibroblasts. J Immunol 165:5255-5261
47. Schechner V, Shapira I, Berliner S, Comaneshter D, Hershcovici T, Orlin J, Zeltser D, Rozenblat M, Lachmi K, Hirsch M, Beigel Y 2003 Significant dominance of fibrinogen over immunoglobulins, C-reactive protein, cholesterol and triglycerides in maintaining increased red blood cell adhesiveness/ aggregation in the peripheral venous blood: a model in hypercholesterolaemic patients. Eur J Clin Invest 33:955-961
48. Deeg M, Bierman E, Cheung M 2001 GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex. J Lipid Res 42:442-451
49. Vowinkel T, Mori M, Krieglstein C, Russell J, Saijo F, Bharwani S, Turnage R, Davidson W, Tso P, Granger D, Kalogeris T 2004 Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest 114:260-269
50. Park Y, Choi H, Kim M, Lee W, Song J, Kim D, Lee S 2002 Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 113:188-193
51. Minoguchi M, Minoguchi S, Aki D, Joo A, Yamamoto T, Yumioka T, Matsuda T, Yoshimura A 2003 STAP-2/BKS, an adaptor/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif. J Biol Chem 278:11182-11189
52. Ramji DP, Foka P 2002 CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 365:561-575
53. Pfitzner E, Kliem S, Baus D, Litterst CM 2004 The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des 10:2839-2850
54. Cantwell CA, Sterneck E, Johnson PF 1998 Interleukin-6-specific activation of the c/ebp-Δ gene in hepatocytes is mediated by stat3 and sp1. Mol Cell Biol 18:2108-2117
55. Tineke CT, van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJM, Kraan MC, Fero M, Tak P-P, Huizinga TWJ, Pieterman E, Breedveld FC, Alizadeh AA, Verweij CL 2003 Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 48:2132-2145
56. Yamaji T, Mitsuki M, Teranishi T, Hashimoto Y 2005 Characterization of inhibitory signaling motifs of the natural killer cell receptor Siglec-7: attenuated recruitment of phosphatases by the receptor is attributed to two amino acids in the motifs. Glycobiology 15:667-676
57. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Flipovich A, Grom AA 2005 Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 7:R30-R37
58. Higuma-Myoju S, Sasaki Y, Miyazaki S, Sakai M, Siozaki A, Miwa N, Saito S 2005 Cytokine profile of natural killer cells in early human pregnancy. Am J Reprod Immunol 54:21-29
59. Shanahan CM 2005 Vascular calcification. Curr Opin Nephrol Hypertens 14:361-367
60. Li M-S, Ma Q-L, Chen Q, Liu X-H, Li P-F, Du G-G, Li G 2005 α-Fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J Gastroenterol 11:2564-2569